Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 2016 2017 2018 2019 (e) 2020 (e) 2021 (e)
Sales 4 860 5 872 6 711 7 654 8 186 8 647
EBITDA 1 435 2 732 3 110 3 166 3 666 3 853
Operating profit (EBIT) 1 331 2 080 2 534 2 327 2 907 2 832
Pre-Tax Profit (EBT) 1 330 2 079 2 554 2 249 2 894 2 814
Net income 896 1 199 2 444 1 970 2 460 2 449
P/E ratio 47,7x 36,4x 17,5x 17,8x 14,5x 14,5x
EPS ( $ ) 7,70 10,3 21,3 17,1 21,0 20,9
Dividend per Share ( $ ) - - - - - -
Yield - - - - - -
Reference price ( $ ) 367,090 375,960 373,500 303,820 303,820 303,820
Announcement Date 02/09/2017
11:30am
02/08/2018
11:30am
02/06/2019
11:30am
- - -
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 2016 2017 2018 2019 (e) 2020 (e) 2021 (e)
Debt - - - - - -
Finance 56,4 706 2 101 6 158 7 635 10 469
Operating income (EBITDA) 1 435 2 732 3 110 3 166 3 666 3 853
Leverage
(Debt/EBITDA)
- - - - - -
Capital Expenditure 512 273 383 418 439 443
Free Cash Flow (FCF) 961 1 034 1 812 2 404 2 547 2 762
Book Value Per Share (BVPS) ( $ ) 42,5 57,1 76,3 110 140 170
Cash Flow per Share ( $ ) 12,7 11,3 19,1 24,4 23,6 24,3
Announcement Date 02/09/2017
11:30am
02/08/2018
11:30am
02/06/2019
11:30am
- - -
Balance Sheet Analysis
Assessed data source
© 2019 S&P Global Market Intelligence
Financial Ratios

Size 2019e 2020e
Capitalization 33 245 M $ -
Entreprise Value (EV) 27 086 M $ 25 609 M $
Valuation 2019e 2020e
P/E ratio (Price / EPS) 17,8x 14,5x
Capitalization / Revenue 4,34x 4,06x
EV / Revenue 3,54x 3,31x
EV / EBITDA 8,55x 7,39x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 2,75x 2,17x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) 30,4% 35,5%
Operating Leverage (Delta EBIT / Delta Sales) - 3,59x
Net Margin (Net Profit / Revenue) 25,7% 30,1%
ROA (Net Profit / Asset) 17,9% 17,2%
ROE (Net Profit / Equities) 23,2% 21,8%
Rate of Dividend - -
Balance Sheet Analysis 2019e 2020e
CAPEX / Sales   5,46% 5,36%
Cash Flow / Sales 34,9% 31,6%
Capital Intensity (Assets / Sales) 1,43x 1,75x
Financial Leverage (Net Debt / EBITDA) - -
EPS & Dividend